Abstract
For 30 years, double-stranded RNA has been used in veterinary applications but has been considered too toxic for human use. However, recent molecular manipulation techniques have improved its tolerability, resulting in the agent ‘Ampligen’ [HemispheRx], which has been approved by the US FDA for clinical trials. The potential of ‘Ampligen’ for treating patients with chronic fatigue syndrome (CFS) was discussed at an international meeting entitled ‘The Clinical and Scientific Basis of Chronic Fatigue Syndrome: From Myth Towards Management’ [ Sydney, Australia; February 1998 ].
Rights and permissions
About this article
Cite this article
Harrigan, P. ‘Ampligen’. Inpharma Wkly. 1128, 9–10 (1998). https://doi.org/10.2165/00128413-199811280-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199811280-00015